February 2, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

SymBio Announces Cooperative Agreement with the NIH to Test IV Brincidofovir for Treating Progressive Multifocal Leukoencephalopathy

TOKYO, Japan, February 2, 2026 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "the Company") today announced that the Company has entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH), entitled "The use of Collaborator's [the Company's] Brincidofovir for the treatment of progressive multifocal leukoencephalopathy (PML)."

Under the CRADA, the NIH/NINDS and the Company will work together to conduct a pilot clinical trial to investigate the use of intravenous (IV) Brincidofovir (BCV) as an antiviral against JC virus (JCV) in the treatment of PML, a rare, life-threatening brain disease.

The trial will be led by Irene Cortese, M.D., chief of the NINDS Experimental Immunotherapeutics Unit at the NIH Clinical Center Bethesda, Maryland, enrolling 18 patients with PML. Preclinical studies conducted by the laboratory of Dr. Aron Lukacher at The Penn State College of Medicine, Philadelphia, have indicated that BCV exhibits potent antiviral activity against mouse polyomavirus. The PML clinical study is designed to evaluate the efficacy and safety of IV BCV in patients with PML. This CRADA is the Company's third with the NIH.

"An anti-viral agent directly targeting the causative agent of PML would represent a ground-breaking advance that would meaningfully change the current treatment landscape, both for patients with PML as well as those requiring treatments that put them at risk for this devastating disease," said Dr. Cortese. "I am hopeful that IV BCV may prove capable of fulfilling this important unmet need."

PML is a severe brain disease caused by JC virus (a polyomavirus) infection of the central nervous system. There is currently no established standard therapy. The disease most often occurs in patients with impaired or suppressed cellular immunity, is associated with high mortality, and is characterized by rapid clinical deterioration with a short interval from diagnosis to progression and death.

Mr. Fuminori Yoshida, the Company's President and CEO, commented: "We are honored to be partnering with NIH/NINDS to take on the uncharted challenge of treating PML. In addition to our

ongoing clinical programs in post-transplant infections and oncology, this PML study will further advance our development into neurodegenerative disorders."

The Company expects no material change to its financial outlook for the fiscal year ending December 31, 2026.

[Contact]
Investor Relations
Tel: +81 (0)3 5427 1125

Note

1: Cooperative Research and Development Agreement (CRADA)

A CRADA is a formal agreement that facilitates research and development collaborations between a federal laboratory and a non-federal partner, such as a private company or university, to jointly pursue common research goals. Its purpose is to make available government facilities, intellectual property, and expertise for collaborative interactions that lead to the development of useful, marketable products that benefit public health. Under this CRADA, an NIH/NINDS-sponsored, investigator-initiated clinical study will be conducted to generate clinical insights on IV BCV in PML, with the aim of informing potential regulatory submissions and further clinical development.

2. Progressive Multifocal Leukoencephalopathy (PML)

PML is a rare, devastating disease caused by reactivation of JC virus in patients with impaired cellular immunity. There is no validated standard therapy, mortality is high, and there is a significant unmet medical need for new treatments. In a collaborative mouse study with The Penn State College of Medicine, SymBio observed high activity of BCV against a polyomavirus (a type of JC virus). These findings were published by Dr. Lukacher's group in mBio in July 2024.

BCV's Business Strategy Based on Three Therapeutic Pillars

Since acquiring the global license to BCV in September 2019, SymBio has been conducting collaborative research with world-class research institutions to unlock BCV's potential in three therapeutic areas. Currently, our management resources and development efforts are centered on three therapeutic pillars: (1) viral infections post-HSCT, (2) hematologic malignancies and solid tumors, and (3) neurodegenerative diseases. SymBio is focusing on its business globally to maximize the business value of BCV.